Dysexecutive Syndrome A Specific Pattern of Cognitive Impairment in Systemic Sclerosis PDF Print E-mail
Sunday, 07 July 2013 20:31
Systemic sclerosis (SSc), also called scleroderma, is a connective-tissue disorder characterized by obliterative microvascular lesions and diffuse interstitial fibrosis. SSc damages the small and medium-sized vessels serving the skin, joints (especially fingers and toes), and internal organs such as the lungs, gastrointestinal tract, kidneys, and heart. In most patients, neurological involvement is limited, and localized to the peripheral nervous system. Raynaud phenomenon (RP) is a prominent early vascular feature of SSc, affecting 90% of patients during their disease course and, in some, progressing
to severe ischemia.

Although the typical manifestation of neurological involvement in SSc is mononeuropathy or polyneuropathy, some imaging studies have reported cerebral hypoperfusion and acute cerebral vasculitis. Cognitive dysfunction is one of the important signs of neurological involvement in systemic lupus erythematosus, affecting up to 80% of patients. In most, the cognitive dysfunction is attributed to RP or antiphospholipid antibodies.

Although RP is a well-known feature of SSc, little is known about cognitive functioning in SSc. Limited data from small series suggest possible impairment. In our study, we aimed to evaluate cognitive functioning in patients with SSc who had no manifest sign of neurological involvement and to determine whether they showed a specific pattern of cognitive impairment that might be caused by cerebral hypoperfusion.

To continue reading the full study, please download from the link provided below.

 
More articles :

» Natural Alternatives for Dealing With Scleroderma

In a recent article, it was noted that conventional medicine attempts to treat the symptoms of with immunosuppressant drugs, NSAIDS and , but has no cure and little advice for prevention. It was noted however, that the world of natural healing has...

» Prevention Of Vascular Damage In Scleroderma With Angiotensin-converting Enzyme (ACE) Inhibition

Great strides have been made in identifying and managing the organ-based complications of  systemic sclerosis (SSc). There is no room for the nihilism towards treating this disease that used to be so prevalent. However, there is still...

» Preliminary Results Show Beneficial Effects of Imatinib in Scleroderma

Imatinib (Gleevec), a drug that has significantly improved survival in chronic myelogenous leukemia and gastrointestinal stromal tumor, is showing beneficial effects on skin and lung manifestations in patients with diffuse cutaneous scleroderma....

» Systemic Sclerosis and Multiple Cancers of the Female Genital Tract

Georgios Androutsopoulos, Georgios Adonakis, Athanasios Tsamandas, Andreas Andonopoulos, Georgios Decavalas.Background: Systemic sclerosis is a rare, chronic, multisystem, autoimmune disease. There is an overall increased risk of malignancy in...

» Researchers Identify Core Genetic Switch As A Viable Target For New Scleroderma Treatments

Scleroderma is a rare, autoimmune disease. Often fatal, it causes the fibrosis or thickening of the connective tissue which support the skin and other vital organs within the body, through the overproduction of . The disease currently lacks a cure...

» An Approach to the Treatment of Scleroderma

Systemic sclerosis is unique among the rheumatic diseases because it presents the challenge of managing a chronic multisystem autoimmune disease with a widespread obliterative vasculopathy of small arteries that is associated with varying degrees of...